AC Immune Advances NLRP3 Inhibitor ACI-19764 in Phase 1
LAUSANNE, Switzerland, August 20, 2026 AC Immune SA announced positive preliminary Phase 1 clinical data for ACI-19764, its wholly...
AC Immune
Advertisement
AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
AC Immune Reports Positive Phase 1 ALS Imaging Data for ACI-19626
LAUSANNE, Switzerland, May 22, 2026 AC Immune announced new preliminary Phase 1 data showing that its investigational TDP-43 PET...
AC Immune Advances ACI-24 Alzheimer’s Trial Expansion
LAUSANNE, Switzerland, April 2026 AC Immune SA announced continued progress in its Phase 1b/2 ABATE clinical trial evaluating ACI-24,...
AC Immune’s Phase 2 Data Shows Promise in Slowing Parkinson’s Progression
LAUSANNE, Switzerland — December 11, 2025 — AC Immune SA has released positive interim Phase 2 data for its...
Advertisement
